Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.

Thomsen FB, Røder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Brasso K.

Clin Genitourin Cancer. 2019 Aug;17(4):e814-e821. doi: 10.1016/j.clgc.2019.05.005. Epub 2019 May 21.

PMID:
31196798
2.

Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.

Filippou P, Welty CJ, Cowan JE, Perez N, Shinohara K, Carroll PR.

Eur Urol. 2015 Sep;68(3):458-63. doi: 10.1016/j.eururo.2015.06.011. Epub 2015 Jun 29.

PMID:
26138041
3.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

4.

Immediate versus delayed prostatectomy: Nationwide population-based study (.).

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, Stattin P.

Scand J Urol. 2016 Aug;50(4):246-54. doi: 10.3109/21681805.2016.1166153. Epub 2016 Apr 12.

5.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

6.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
7.

Sexual function with localized prostate cancer: active surveillance vs radical therapy.

van den Bergh RC, Korfage IJ, Roobol MJ, Bangma CH, de Koning HJ, Steyerberg EW, Essink-Bot ML.

BJU Int. 2012 Oct;110(7):1032-9. doi: 10.1111/j.1464-410X.2011.10846.x. Epub 2012 Jan 19.

8.

External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.

Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, Soria F, Mattei A, Montorsi F, Briganti A, Shariat SF.

Eur Urol. 2019 Feb;75(2):319-328. doi: 10.1016/j.eururo.2018.09.034. Epub 2018 Oct 4.

PMID:
30293908
9.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

10.

Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.

Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, Kim SJ, Rha KH, Hong SJ, Chung BH.

Cancer Res Treat. 2018 Jan;50(1):129-137. doi: 10.4143/crt.2017.004. Epub 2017 Mar 8.

11.

Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.

Heering M, Berg KD, Brasso K, Iversen P, Røder MA.

Surg Oncol. 2017 Mar;26(1):21-27. doi: 10.1016/j.suronc.2016.12.002. Epub 2016 Dec 8.

PMID:
28317581
12.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

13.

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):407-412. doi: 10.1038/pcan.2017.29. Epub 2017 May 9.

PMID:
28485390
14.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

15.

Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.

Gearman DJ, Morlacco A, Cheville JC, Rangel LJ, Karnes RJ.

J Urol. 2018 May;199(5):1188-1195. doi: 10.1016/j.juro.2017.11.116. Epub 2017 Dec 7.

PMID:
29225057
16.

A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.

Lee JY, Cho KS, Kwon JK, Jeh SU, Kang HW, Diaz RR, Ham WS, Koom WS, Keum KC, Choi YD.

Ann Surg Oncol. 2014 Nov;21(12):4026-33. doi: 10.1245/s10434-014-3780-9. Epub 2014 May 20.

PMID:
24841351
17.

External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.

Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1045-1052. doi: 10.1016/j.ijrobp.2017.03.040. Epub 2017 Mar 31.

PMID:
28721887
18.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

19.

Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.

Venderbos LDF, Aluwini S, Roobol MJ, Bokhorst LP, Oomens EHGM, Bangma CH, Korfage IJ.

Qual Life Res. 2017 Jun;26(6):1635-1645. doi: 10.1007/s11136-017-1507-7. Epub 2017 Feb 6.

20.

Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.

Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF.

JAMA. 2017 Mar 21;317(11):1126-1140. doi: 10.1001/jama.2017.1704. Erratum in: JAMA. 2017 May 23;317(20):2134.

Supplemental Content

Support Center